actr2b Antibody

What is ACVR2B and why is it important in research?

ACVR2B (also known as ACTR-IIB, ActR-IIB, or HTX4) is a transmembrane serine/threonine kinase activin type-2 receptor that forms a complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B, or ACVR1c). This receptor is critical in research because it transduces activin signals from the cell surface to the cytoplasm, regulating numerous physiological and pathological processes including neuronal differentiation and survival, hair follicle development, FSH production, wound healing, extracellular matrix production, immunosuppression, and carcinogenesis . Its involvement in the myostatin signaling pathway makes it particularly important for muscle biology research .

What are the structural characteristics of ACVR2B protein?

ACVR2B is a protein with a calculated molecular weight of approximately 57.7 kDa (57724 Da) . It belongs to the TGF-beta superfamily of receptor ser/thr kinases. The protein maintains amino acid homology with other TGF-beta family members, particularly in the conservation of 7 of the 9 cysteine residues common to all TGF-beta forms . The human ACVR2B is identified by UniProt ID Q13705 and Entrez Gene ID 93 . Structurally, the protein contains distinct domains including a ligand-binding extracellular domain that can be targeted for therapeutic approaches, such as in the creation of soluble ACVR2B/Fc fusion proteins .

How do I select the appropriate ACVR2B antibody for my research?

Selection of an appropriate ACVR2B antibody depends on several factors:

• Research application: Different antibodies are optimized for specific applications:

  • For Western blotting: Consider antibodies validated for WB applications

  • For immunohistochemistry: Look for antibodies tested in IHC or IHC-p

  • For neutralization studies: Select antibodies with demonstrated neutralization capacity

  • For flow cytometry: Use antibodies specifically validated for FCM

• Species reactivity: Verify cross-reactivity with your species of interest (human, mouse, rat, etc.)

• Epitope region: Consider the antibody's target region within ACVR2B:

  • N-terminal antibodies (aa 1-30)

  • Middle region antibodies

  • Antibodies targeting specific functional domains

• Clonality: Determine whether polyclonal or monoclonal antibodies better suit your needs:

  • Polyclonal: Broader epitope recognition but potentially lower specificity

  • Monoclonal: Higher specificity for a single epitope

• Validation data: Review available validation information including Western blot images, published citations, and functional neutralization data

How can I use ACVR2B antibodies to study receptor-ligand interactions?

Studying ACVR2B receptor-ligand interactions requires specialized methodological approaches:

Neutralization assays: Some ACVR2B antibodies have been validated for neutralization capacity. For example, when used at 1-3 µg/mL, certain antibodies will block 50% of the binding of 30 ng/mL recombinant human activin A to immobilized recombinant human activin receptor IIB/Fc chimera (using 100 µL of a 0.5 µg/mL solution coating each well) in an ELISA assay . This approach allows for functional analysis of receptor-ligand binding.

Co-immunoprecipitation studies: For investigating protein-protein interactions between ACVR2B and its binding partners (activin-A/INHBA, activin-B/INHBB, inhibin-A/INHA-INHBA), use antibodies validated for immunoprecipitation to pull down receptor complexes followed by Western blot analysis of associated proteins .

Receptor dimerization analysis: Since ACVR2B forms complexes with type I receptors, crosslinking studies combined with immunoprecipitation can reveal dimerization patterns and stoichiometry.

What are the best methods for analyzing ACVR2B-mediated signaling pathways?

Analysis of ACVR2B-mediated signaling requires multi-faceted approaches:

SMAD signaling assessment: Upon ligand binding, ACVR2B phosphorylates and activates type-1 receptors, which subsequently phosphorylate SMAD2/3. This pathway can be monitored by:

• Measuring phosphorylated SMAD2/3 levels via Western blot

• Immunofluorescence to track SMAD nuclear translocation

• Luciferase reporter assays using SMAD-responsive elements

Non-SMAD pathway analysis: ACVR2B also signals through non-canonical pathways, which can be studied by monitoring the activation of:

• MAPK pathways (ERK1/2, p38, JNK)

• PI3K/AKT signaling

• mTOR regulation

Inhibitor studies: Using specific pathway inhibitors in combination with ACVR2B neutralizing antibodies can dissect the contribution of different downstream pathways.

Genetic approaches: Complementing antibody studies with genetic knockdown/knockout models of ACVR2B and related receptors (e.g., ACVR2) can reveal receptor redundancy and pathway specificity .

How do I design experiments to study functional redundancy between ACVR2 and ACVR2B receptors?

Research has demonstrated functional redundancy between ACVR2 and ACVR2B receptors. To design experiments investigating this redundancy:

Receptor targeting approaches:

• Use conditional knockout models targeting either Acvr2, Acvr2b, or both simultaneously in specific tissues (e.g., using Myl1-cre for muscle-specific deletion)

• Analyze receptor expression by qPCR to ensure successful targeting and to verify that compensatory upregulation of other receptors does not occur

Phenotypic analysis:

• Quantify tissue-specific effects (e.g., muscle mass in single vs. double receptor knockout models)

• Compare the magnitude of effects between single and double receptor targeting

Antibody-based studies:
Highly specific monoclonal antibodies directed against each receptor (with no cross-reactivity) have demonstrated additive effects in stimulating muscle growth when administered together, further confirming functional redundancy .

How can ACVR2B antibodies be utilized in myostatin signaling research?

ACVR2B is a primary receptor for myostatin (MSTN), a negative regulator of muscle growth. Research methodologies using ACVR2B antibodies include:

Myostatin binding studies:

• Use ACVR2B antibodies in competition assays to evaluate myostatin binding sites

• Employ neutralizing antibodies to block myostatin-ACVR2B interactions and assess functional outcomes

Receptor specificity analysis:

• Compare effects of targeting ACVR2B vs. ACVR2 on myostatin signaling

• Utilize antibodies with differential specificity to these receptors to determine their relative contributions to myostatin effects

Therapeutic model testing:

• Use ACVR2B antibodies in muscle wasting models (e.g., cachexia, muscular dystrophy)

• Combine with muscle regeneration studies to assess both hypertrophic and regenerative effects

What methods can be used to study ACVR2B inhibition in muscle regeneration?

Research has demonstrated that inhibition of the ACVR2B pathway can restore muscle regeneration in challenging conditions. Methodological approaches include:

Satellite cell depletion models:

• Use genetic models (e.g., Pax7DTR/+ mice) where satellite cells can be conditionally depleted

• Administer ACVR2B pathway inhibitors (e.g., RAP-031) and assess regenerative capacity

Cellular analysis methods:

• FACS sorting of muscle stem cells using appropriate markers (CD34, Sca1, PDGFRα)

• Immunofluorescence techniques to identify and quantify satellite cells and other progenitor populations using markers like PW1, Pax7, and M-Cadherin

• Proliferation analysis using Ki67 staining

What are the methodological considerations when developing decoy receptors vs. antibodies targeting ACVR2B?

Two main approaches have been developed for therapeutically targeting ACVR2B:

Decoy receptor (ACVR2B/Fc) approach:

• Generate soluble forms of ACVR2B by fusing the ligand-binding domain to an immunoglobulin Fc domain

• This creates a ligand trap capable of binding multiple ligands that interact with ACVR2B

• Protocol considerations:

  • Expression in appropriate cell systems (typically mammalian cells)

  • Purification strategies preserving protein conformation

  • Functional validation through ligand binding assays

• Advantage: Extremely potent in promoting muscle growth (>50% in just 2 weeks with high doses)

• Limitation: Not specific to a single ligand; blocks multiple signaling pathways

Monoclonal antibody approach:

• Develop antibodies specifically targeting ACVR2B (e.g., bimagrumab/BYM338)

• Methodological considerations:

  • Antibody specificity testing (cross-reactivity with related receptors)

  • X-ray crystallography analysis to determine exact binding sites

  • Affinity measurements and optimization

• Advantage: Can be engineered for receptor specificity

• Example: Although early reports suggested bimagrumab had >200-fold higher affinity for ACVR2B compared to ACVR2, crystallography later showed it blocks the ligand-binding domain of both receptors

What are the optimal conditions for Western blot analysis using ACVR2B antibodies?

Successful Western blot analysis of ACVR2B requires attention to several technical factors:

Sample preparation:

• Given its transmembrane nature, use lysis buffers containing appropriate detergents (e.g., RIPA buffer with 1% NP-40 or Triton X-100)

• Include protease and phosphatase inhibitors to prevent degradation

• For membrane proteins like ACVR2B, avoid excessive heating during denaturation (65°C rather than 95°C)

Electrophoresis and transfer conditions:

• Expect detection around the calculated molecular weight of ~57.7 kDa

• Use appropriate gel percentage (8-10% SDS-PAGE) for this molecular weight range

• Consider wet transfer for more reliable results with membrane proteins

Antibody dilutions and detection:

• Typical working dilutions range from 1:1000 to 1:3000, but optimize for each specific antibody

• Include appropriate blocking (typically 5% non-fat milk or BSA)

• Consider enhanced chemiluminescence detection for optimal sensitivity

Controls and validation:

• Include positive controls (tissues/cells known to express ACVR2B)

• Use recombinant ACVR2B protein as a standard when available

• Consider knockdown/knockout samples as negative controls

How can I optimize immunohistochemistry protocols for ACVR2B detection in different tissues?

Successful IHC detection of ACVR2B requires protocol optimization:

Fixation considerations:

• Formalin-fixed paraffin-embedded (FFPE) tissues typically require antigen retrieval

• For ACVR2B, heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is often effective

Antibody selection and optimization:

• Choose antibodies validated specifically for IHC applications

• Starting dilutions typically range from 1:100 to 1:200

• Optimize incubation conditions (temperature, time)

Signal detection methods:

• For chromogenic detection, DAB (3,3'-diaminobenzidine) is commonly used

• For fluorescence detection, use appropriate secondary antibodies coupled to fluorophores like Alexa Fluor 488, Cy3, or Cy5

Tissue-specific considerations:

• Muscle tissue: Co-staining with laminin helps visualize fiber boundaries

• For quantitative analyses, count positive cells across multiple randomly chosen fields (minimum 5 fields per muscle section)

• Example protocol: For cross-sections of rat stomach, use rabbit anti-ACVR2B polyclonal antibody at 1:200 dilution followed by secondary antibody conjugation and DAB staining

What are the common challenges in ACVR2B antibody experiments and how to address them?

Challenge 1: Antibody cross-reactivity with related receptors

• Solution: Use antibodies with validated specificity

• Method: Test antibodies against recombinant ACVR2, ACVR2B, and other related receptors

• Approach: Consider using monoclonal antibodies directed against unique epitopes

Challenge 2: Distinguishing splice variants

• Problem: Five splice variants of ACVR2B have been reported

• Solution: Select antibodies targeting conserved or variant-specific regions

• Validation: Verify by Western blot that the antibody detects the expected variant(s)

Challenge 3: Low signal-to-noise ratio in IHC/IF

• Solutions:

  • Optimize blocking conditions (try different blockers: BSA, normal serum, commercial blockers)

  • Increase antibody concentration incrementally

  • Extend primary antibody incubation time (overnight at 4°C)

  • Test different antigen retrieval methods

Challenge 4: Functional redundancy complicating interpretation

• Context: ACVR2 and ACVR2B show functional redundancy

• Solution: Use combined approaches:

  • Specific blocking of individual receptors

  • Double-blocking experiments

  • Genetic models with single vs. double receptor targeting

How are ACVR2B antibodies being used in cancer research?

ACVR2B signaling has implications in carcinogenesis and cancer progression. Methodological approaches include:

Signaling pathway analysis in cancer cells:

• Evaluate ACVR2B expression levels across cancer types

• Use neutralizing antibodies to block ACVR2B signaling and assess impact on:

  • Proliferation

  • Migration and invasion

  • Resistance to therapy

  • Immune evasion mechanisms

Tumor microenvironment studies:

• Investigate how ACVR2B signaling influences stromal cells and immune components

• Use antibodies for immunoprofiling of ACVR2B expression in tumor biopsies

Therapeutic targeting:

• Evaluate ACVR2B antibodies alone or in combination with standard treatments

• Develop strategies to limit cachexia (muscle wasting) in cancer patients through ACVR2B pathway inhibition

What methods are used to investigate ACVR2B antibodies in neurological research?

ACVR2B is involved in neuronal differentiation and survival . Research methodologies include:

Neurodevelopmental studies:

• Use ACVR2B antibodies to track receptor expression during neural development

• Block ACVR2B signaling at different developmental timepoints to assess impact on:

  • Neuronal differentiation

  • Axonal growth and pathfinding

  • Synaptogenesis

Neuroprotection research:

• Apply ACVR2B neutralizing antibodies in models of neuronal injury

• Assess survival, regeneration, and functional recovery

• Investigate molecular mechanisms through downstream signaling analysis

Methodological approaches:

• Primary neuron cultures treated with ACVR2B antibodies

• Organoid models for 3D assessment of neural development

• In vivo models with targeted ACVR2B blockade